Breaking News

Cristal Therapeutics, PX Biosolutions to Develop Nanotech Vax Platform

Aims to develop superior vaccine products using CriVac technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cristal Therapeutics has entered a collaboration with PX Biosolutions to research and develop the application of Cristal’s nanotechnology platform CriVac, for the design of innovative vaccines.   The CriVac platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, allowing optimal antigen presentation to dendritic cells.   PX Biosolutions, based in Melbourne, Australia, has developed DCtag vaccine formulations against various types of cancer. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters